The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented is solely approved for use in the US by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The compound is still being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
European Society of Cardiology Congress 2021 Industry Session Sponsored by Bayer August 27–30, 2021
Presentations of the Bayer Industry Symposium at the ESC Congress 2021
Thank you for your interest! Please see below to download PDFs of the presentation of the Bayer Industry Symposia at the ESC Congress 2021. Access to the presentations will be available after the congress presentation including a full reference list at the end of the page.
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Finerenone
Sunday 29 August, 2021 | 16:52 - 17:00 CEST
Exploring the cardiorenal benefits of MR antagonism in CKD and T2D
How to improve cardiorenal outcomes in patients with CKD and T2D?
Session: Satellite SymposiumSpeaker: Michele Senni
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Sunday 29 August, 2021 | 17:00 - 17:15 CEST
Exploring the cardiorenal benefits of MR antagonism in CKD and T2D
Cardiovascular and kidney benefits of MR antagonism: Insights from the FIGARO-DKD and FIDELIO-DKD trials
Session: Satellite SymposiumSpeaker: Gerasimos Filippatos
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Additional reading
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. The Journal of Biological Chemistry
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nature Reviews Nephrology
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Design and baseline characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease trial. American Journal of Nephrology
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. The New England Journal of Medicine
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. Journal of Cardiovascular Pharmacology
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. The Journal of Biological Chemistry
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. Journal of the American College of Cardiology
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Kidney disease and increased mortality risk in type 2 diabetes. Journal of the American Society of Nephrology
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Mineralocorticoid receptor and cardiovascular disease. American Journal of Hypertension
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Nonsteroidal antagonists of the mineralocorticoid receptor. Current Opinion in Nephrology
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Nuclear receptors in bone physiology and diseases. Physiological Reviews
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Failure Reviews
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Selective mineralocorticoid receptor-cofactor modulation as molecular basis for finerenone’s anti-fibrotic activity in a preclinical model of cardiac fibrosis. Hypertension
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney International
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Heart Failure
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
The mineralocorticoid receptor and its coregulators. Journal of Molecular Endocrinology
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. Cardiovascular Research
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
The multifaceted mineralocorticoid receptor. Comprehensive Physiology
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Type 2 diabetes in older patients: An analysis of the DPV and DIVE databases. Therapeutic Advances in Endocrinology and Metabolism
Date accessed: 1 September, 2021
Click on the links below to access the following references. You will be redirected to a new webpage. Please note, you may have to be logged in to the publication or pay to access the following literature.
Vascular mineralocorticoid receptor: Evolutionary mediator of wound healing turned harmful by our modern lifestyle. American Journal of Hypertension
Date accessed: 1 September, 2021
MA-M_FIN-ALL-0422-1